Purple Biotech (formerly known as Kitov Pharmaceuticals) is a company focusing on advancing therapies to overcome tumor immune evasion and drug resistance, to create long-lasting treatments for people with cancer. Its oncology pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. CM-24 is a monoclonal antibody blocking CEACAM1, an immune checkpoint that supports tumor immune evasion and survival through multiple pathways.